Biogen Idec, Inc. (Massachusetts) (BIIB) and Sobi Present New Data From the Phase 3 Study of Their Long-Lasting Hemophilia Factor Candidate ALPROLIX
7/2/2013 2:05:24 PM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
WESTON, Mass. and STOCKHOLM--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today presented new findings for their long-lasting recombinant factor IX candidate ALPROLIX* for hemophilia B at the XXIV International Society on Thrombosis and Haemostasis (ISTH) Congress in Amsterdam, The Netherlands. Three oral presentations showcase new data that reinforce the potential safety, efficacy and pharmacokinetic profile of ALPROLIX. The data highlight the consistency of results with ALPROLIX across patient types and favorable physician ratings of its efficacy in treating acute bleeding episodes and controlling bleeding during and after major surgery.
Help employers find you! Check out all the jobs and post your resume.
comments powered by